NASHVILLE – Many more breast cancer patients now opt for mastectomy, including removal of both breasts, instead of choosing breast conservation surgery (BCS), even with early-stage disease confined to one breast, according to a new study.
The rates of increase were steepest among women with lymph node-negative and in situ disease, according to Vanderbilt University researchers, who noted the reversal of trends seen since the 1990s, when BCS was found to produce equivalent cancer outcomes and was endorsed as a standard of excellence by a National Institutes of Health Consensus Conference.
The study, published online recently by JAMA Surgery, was funded by the VA and used facilities of the VA Tennessee Valley Healthcare System in Nashville.1
For the study, researchers used the National Cancer Data Base to study records of more than 1.2 million adult women treated at centers accredited by the American Cancer Society and the American College of Surgeons Commission on Cancer from Jan. 1, 1998, to Dec. 31, 2011.
In that time period, 35.5% of those women underwent mastectomy, with the adjusted odds of mastectomy in BCS-eligible women increasing 34% during the most recent eight years of the study period. Rates of bilateral mastectomy as a result of cancer in one breast increased from 1.9% to 11.2% from 1998 to 2011.
In women undergoing mastectomy, rates of breast reconstruction increased from 11.6% to 36.4% in the same time period.
Mastectomy rate increases in the U.S. were especially common in younger women with noninvasive disease, those with smaller tumors and those with node-negative disease, indicating the cancer was less likely to spread beyond the initial tumor, according to the study.
Despite limited evidence to support the practice, testing for Helicobacter pylori (Hp) infection is recommended for work-up of unexplained iron deficiency anemia (IDA).
SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1